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ABSTRACT 
Class IIa bacteriocins are potent antimicrobial peptides produced by lactic acid bacteria to 
destroy competing microorganisms.  The N-terminal domain of these peptides consists of a 
conserved YGNGV sequence and a disulphide bond.  The YGNGV motif is essential for activity, 
whereas, the two cysteines involved in the disulphide bond can be replaced with hydrophobic 
residues.  The C-terminal region has variable sequences, and folds into a conserved amphipathic 
α-helical structure.  To elucidate the structure-activity relationship in the N-terminal domain of 
these peptides, three analogues (1-3) of a class IIa bacteriocin, Leucocin A (LeuA), were 
designed and synthesized by replacing the N-terminal -sheet residues of the native peptide with 
shorter -turn motifs.  Such replacement abolished the antibacterial activity in the analogues, 
however, analogue 1 was able to competitively inhibit the activity of native LeuA.  Native LeuA 
(37-mer) was synthesized using native chemical ligation method in high yield.  Solution 
conformation study using circular dichroism spectroscopy and molecular dynamics simulations 
suggested that the C-terminal region of analogue 1 adopts helical folding as found in LeuA, 
while the N-terminal region did not fold into -sheet conformation.  These structure-activity 
studies highlight the role of proper folding and complete sequence in the activity of class IIa 
bacteriocins. 
 
Keywords: Antimicrobial peptide; Class IIa bacteriocins; Leucocin A (LeuA); Solid phase 
peptide synthesis; Native chemical ligation; Antimicrobial activity; Solution conformation; 
Structure-activity relationships 
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1. Introduction 
Bacteriocins are potent antimicrobial peptides with a potential in a variety of applications 
such as food preservation, replacement of conventional antibiotics, and treatment of bacterial 
multiple-drug-resistance.1-3  Bacteriocins derived from lactic acid bacteria are produced as a part 
of their self defense mechanism to destroy competing microorganisms.4  Bacteriocins like class I 
nisin and class IIa pediocin PA-1 are currently used for food preservation and their potential in 
medical applications is being explored.1 Class IIa bacteriocins are unmodified cationic peptides 
ranging from 37–48 residues that display activity against a variety of food pathogens, including 
Listeria monocytogenes in the nanomolar range.2 
Bacteriocins display potent activity by one or more of the proposed mechanisms of 
actions.  These peptides can (i) permeabilize the target cell membrane and reduce the proton 
motive force of bacterial cells, (ii) induce lysis of the cell by activating autolysins 1, 5, 6 or (iii) 
bind to the membrane bound receptor and cause pores in the cell wall.7, 8  For class IIa 
bacteriocins, it is becoming clear that peptides act by interacting with a specific receptor, 
mannose phosphotransferase system (PTS) permease, on the target cell membrane and for this 
peptide-receptor interaction folded conformation of the peptide is a key element.  Comparison of 
the amino acid sequence of class IIa bacteriocins shows that these peptides consist of a highly 
conserved hydrophilic and charged N-terminal region harboring the consensus YGNGV 
sequence and a disulfide bond.  The C-terminal region is hydrophobic with a more variable 
sequence.  In contrast, the three dimensional solution structures of several class IIa bacteriocins 
show that N-terminus region folds into different conformations, such as anti-parallel β-sheet or 
coiled structure, and the C-terminal region maintains a conserved amphipathic α-helical 
structure.9-11  The C-terminal helical region imparts target specificity and likely interacts with the 
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target cell membrane bound receptor, whereas the positively charged N-terminal region interacts 
with the cell surface by electrostatic interaction.12-14  
Leucocin A (LeuA) is a 37 residue class IIa bacteriocin from Leuconostoc gelidium.15  A 
series of experiments conducted by Fleury et al.16 to elucidate structure activity relationship 
(SAR) of LeuA show that N-terminal YGNGV sequence and C-terminal tryptophan are essential 
for activity.  The N-terminal of LeuA (residues 2-16) consists of a three stranded anti-parallel β-
sheet which is stabilized by the disulphide bond between residues 9 and 14, and C-terminal 
residues Trp18-Ala30 form an amphipathic -helix. (Figure 1a).9, 17  The conserved disulphide 
bond between two cysteines maintains the correct geometry of other residues in the sequence and 
this geometry is essential for its activity.18 Studies conducted by Derksen et al.18  confirmed that 
the disulphide bond only contributes to maintain correct geometry in the molecule but does not 
bind to the receptor on the bacterial cell membrane.  The authors substituted the disulphide bond 
with carbocyclic rings without losing activity while maintaining flexibility and geometry in the 
synthetic LeuA.  More recently it was shown that the replacement of the two Cys residues in the 
N-terminal region of LeuA with hydrophobic residues such as Phe, Nva (Norvaline), AllylGly 
yields a fully active analogue.19  On the other hand, substitution of the Cys with Ser residues in 
LeuA made the peptide inactive.  These results suggests that although the disulfide bond is 
conserved among class IIa bacteriocins, it can be replaced with residues which can induce 
similar geometry in the molecule without losing its antibacterial activity. 
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Figure 1.  (a)  NMR solution structure of native LeuA (PDB code: 1CW6)9 in 90% TFE.  (b) 
Schematic of the designed LeuA analogues depicting the replacement of a portion of N-terminal 
-sheet region from LeuA with a smaller sequence. (c) Amino acid sequences of native LeuA 
and peptide analogues studied herein. 
 
We hypothesized that analogues of LeuA can be designed by replacing a portion of the 
N-terminal -sheet region (Cys9-Ser15) with a smaller -turn.  To validate this and study the 
SAR of LeuA, three analogues (1-3) of LeuA were designed and synthesized by manipulating 
the N-terminal region of the native LeuA (Figure 1).  LeuA was synthesized as a control 
Peptide Sequencea Charge No. of 
residues 
LeuA 
1 
2 
3 
KYYGNGVHCTKSGCSVNWGEAFSAGVHRLANGGNGFW 
KYYGNGVH--KP---VNWGEAFSAGVHRLANGGNGFW 
KYYGNGVH--KSG---NWGEAFSAGVHRLANGGNGFW 
KYYGNGVH--KPNG---WGEAFSAGVHRLANGGNGFW  
+2 
+2 
+2 
+2 
37 
32 
32 
32 
a For analogues 1-3, residues in black are the same as in the native LeuA sequence, 
green represents mutations, and – stands for deleted residue. 
W18 
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employing native chemical ligation (NCL) of two smaller fragments of LeuA.  The antimicrobial 
activity of analogues and LeuA was evaluated against two indicator strains, Carnobacterium 
divergens and Listeria monocytogenes.  In general the analogues did not show any activity 
whereas synthetic LeuA was highly active.  Interestingly, analogue 1 was able to competitively 
inhibit the activity of LeuA.  Solution conformation study using circular dichroism (CD) 
spectroscopy suggested that only analogue 1 most likely adopts similar helical folding as LeuA.  
Further, molecular dynamics (MD) simulations of 1 revealed that the C-terminal region folds 
into a well-defined -helix, however, the N-terminal region does not form a -sheet structure 
like the native LeuA emphasizing the role of proper folding in the activity of class IIa 
bacteriocins. 
 
2. Results and discussion 
2.1 Design of LeuA Analogues 
As mentioned above, the N-terminal region of LeuA mainly interacts with electrostatic 
interaction with the target cell membrane.  Therefore, the exact role of folded conformation in 
the N-terminal region of class IIa bacteriocins is not clear.  We designed three analogues of 
LeuA by replacing the N-terminal -strand residues ranging from Cys9-Asn17 with smaller -
turn sequences (Figure 1).  The analogues were 32-residue long, five residues less compared to 
the native LeuA.  Lys11 was kept in all the analogues to maintain the overall charge of +2.  The 
-strand residues Cys9-Thr10 and Gly13-Ser15 were deleted in analogue 1, and SerPro 
mutation was introduced to increase the conformational stability of the -turn.  Proline has a 
unique restricted  angle that allows it to be entropically favourable at turn positions.20  In 
analogue 2, the -turn sequence Lys-Ser-Gly (KSG) from the native LeuA was maintained 
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whereas, in analogue 3, the -turn was substituted with another -turn motif, a conserved 
tripeptide sequence Pro-Asx-Gly.21   
 
2.2 Synthesis of LeuA and Analogues 
Peptide analogues 1-3 were synthesized on 2-chlorotrityl chloride resin using Fmoc solid-
phase peptide synthesis.22  Crude peptides were purified using semi-preparative reversed-phase 
HPLC prior to characterization by MALDI-TOF mass spectrometry.  All peptide analogues were 
purified up to >95% purity as shown by analytical RP-HPLC and mass spectrometry (Figure S1, 
SI), and were obtained with an overall yield of 15-30%.   
LeuA (37-mer) is a fairly hydrophobic peptide that gives rise to several truncated 
sequences during stepwise linear synthesis.  We attempted to establish a NCL method23-24 for 
LeuA which allows synthesis of two smaller fragments that are ligated to give the complete 
product.  NCL method leads to high purity, higher yields, low racemisation, low 
aggregation/truncation of peptide, and allows synthesis of larger peptides.  Therefore, it is a 
promising alternative for the synthesis of LeuA and similar peptides.  In order to perform NCL 
reaction of two fragments, the first fragment should have C-terminal thioester and the other 
fragment should have N-terminal cysteine residue.  In general, the fragments are chosen based on 
the presence of cysteine residue somewhere in the middle of the sequence.  However this is not a 
prerequisite as other residues, such as Alanine, can also be chosen at the fragmentation point.23  
After NCL was first reported by Dawson et al,24 a number of peptides, protein, and enzymes 
have been synthesized using this strategy.25 
For the synthesis of LeuA using NCL, Cys14 was chosen as the potential ligation site 
giving rise to two fragments, 13-residue fragment 1 (1-13) and 24-residue fragment 2 (14-37) 
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(Figure 2a).  The NCL reaction is initiated by a chemo selective nucleophilic attack of the thiol 
of Cys (N-terminal) of unprotected peptide fragment 2 on the C-terminal thioester moiety of  
 
 
Figure 2.  (a) Protocol for the synthesis of LeuA using NCL method.  (b)  Progress of the NCL 
reaction monitored using RP-HPLC at time 0, 12 and 24 h.  The two fragments, LeuA-13AA 
(residues 1-13, F1) and LeuA-24AA (residues 14-37, F2) elute at 21 and 39 min, respectively, 
whereas, the ligated product LeuA (residues 1-37) elutes at 26 min. The NCL reaction was 
complete in 24 h. 
 
(a) 
(b) 
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unprotected peptide fragment 1.  This reaction is followed by rapid spontaneous rearrangement, 
through an S-N acyl shift, giving rise to a ligated product.   
The 13-residue fragment 1 (thioester) was synthesized using two different protocols as 
shown in Figure S2.  First method utilizes sulfonamide safety-catch resin for the thioester 
synthesis26, 27 whereas the second method employs thioesterfication of the peptide synthesized 
using 2-chlorotrityl resin.28  For the synthesis using sulfonamide safety catch resin, first amino 
acid Fmoc-Gly (activation with PyBOP) was coupled manually to the 4-sulfamylbutyryl AM 
resin followed by assembly of the remaining amino acids on automated synthesizer.  After 
complete peptide sequence, activation of the sulfonamide with iodoacetonitrile and displacement 
with the thiol nucleophile ethyl-3-mercaptopropionate produced the protected thioester peptide.  
LeuA 1-13 thioester (Fragment 1) was obtained after side chain deprotection using a mixture 
containing TFA, TIS and water.  Typical yield of the HPLC purified fragment 1 synthesized 
using 4-sulfamylbutyryl AM resin was 21 mg (7% based on 0.2 mmol scale).  Fragment 1 was 
characterized by RP-HPLC and MALDI-TOF mass spectrometry.  For the second method, the 
peptide (1-13) was synthesized on 2-chlorotrityl resin.  After cleavage from the resin with 1% 
TFA, peptide with C-terminal carboxylate was obtained which was converted into thioester by 
reaction with DIC, HOBt, DIPEA, and ethyl 3-mercatopropionate.  Finally, the side chain 
protections and N-terminal Boc was removed as done for the first method.  The second method 
gave higher yield (100 mg, 33% based on 0.2 mmol scale) of the pure thioester fragment 1. 
Fragment 2, 24-residue (14-37), was synthesized a 0.2 mmole scale on 2-chloro trityl 
chloride resin following stepwise SPPS.  After purification using RP-HPLC, fragment 2 was 
obtained with an overall yield of 270 mg (55% based on 0.2 mmol scale) and purity greater than 
95%.  Next, the two fragments, fragment 1 thioester (4 mol) and fragment 2 (4 mol), were 
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ligated in phosphate buffer (pH 7.6) containing 6 M GnHCl and thiophenol (4%)/ benzyl 
mecaptan (4%) as catalysts.29  The reaction was monitored at different time intervals (0, 12 h, 24 
h) by RP-HPLC.  As shown in Figure 2b, the ligation was completed in 24 h, after which the 
resultant ligated product was purified using semi-preparative RP-HPLC.  The presence of 
thiophenol with excess with 3-mercaptopropionic acid ethyl ester significantly enhanced the 
ligation reaction rate through nucleophilic catalysis.30  The pure peptide was characterized by 
RP-HPLC and MALDI-TOF mass spectrometry (Figure S3).  The yield of the chemical ligation 
reaction to give pure peptide in the reduced form was 95-98% (14 mg).   
The overall yield of the purified reduced LeuA was 0.06 mmol (30%) on a 0.2 mmol 
scale synthesis.  Oxidative folding or disulfide bond formation of the reduced peptide (14 mg) 
was carried out to give 9.5 mg of oxidized LeuA peptide with an overall yield of 21% based on 
0.2 mmol scale synthesis. 
We also attempted the stepwise SPPS of LeuA using Cl-trityl resin and the overall yield 
of LeuA obtained was 4.2%.  In addition, others have attempted synthesis of Leu A using 
specialized resins such as polyamide/kieselguhr resin with an overall yield 16%.16  Syntheses of 
several unnatural analogues of LeuA, such as ent-LeuA and carba-LeuA and diallyl-LeuA have 
been reported,18, 31, 32  and the overall yield for the analogues has been low, such for  ent-LeuA 
the yield was 6% using Wang resin as a solid support.31  The NCL method certainly seems more 
promising for the synthesis of class IIa bacteriocins and analogues.  Due to the hydrophobic 
nature of these peptides, coupling amino acids after 20-residues to the solid support during 
stepwise SPPS becomes very difficult.  The elongated peptide tends to aggregate most likely due 
to the hydrophobic C-terminal domain leading to the appearance of increased number of 
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truncated peptides. To increase the yield and avoid loss of LeuA due to truncated peptides, 
chemical ligation seems to be a better method for the synthesis of LeuA and analogues. 
 
2.3 Antimicrobial Activity 
The activity spectra of the LeuA analogues 1-3 were evaluated against two indicator 
strains, Carnobacterium divergens and Listeria monocytogenes using liquid growth inhibition 
assay as described previously.18  Synthetic LeuA (or LeuA) was used as a positive control.  LeuA 
displayed potent activity against C. divergens and L. monocytogenes with MIC values of 39 and 
37 nM, respectively (Figure 3a).  These MIC values were similar to the wild type peptide 
reported previously.18, 22  However, none of the analogues (1-3) displayed any activity up to 200 
M concentration.  Next, the ability of analogues 1-3 to inhibit the antimicrobial activity of 
LeuA was explored.  Analogues 2 and 3 did not inhibit the activity of native LeuA, whereas, the 
presence of analogue 1 led to significant inhibition of LeuA activity against C. divergens in a 
dose-dependent manner (Figure 3b).  At high concentration of analogue 1 (100 M), there was 
almost complete inhibition of LeuA activity (OD 0.550.08).  The optical density for the control 
C. divergens sample, without LeuA and analogue 1, was 0.610.09.  These results suggest that 
the C-terminal helical region of analogue 1 may play an important role in mediating specific 
interaction with the target cell membrane receptor. 
The N-terminal sequence in analogue 1 that lacks the -sheet folding is likely responsible 
for inactivity of 1.  Chen et al. previously showed using N-terminal pediocin PA-1 fragments that 
electrostatic interaction direct peptide binding to the target membrane.14  In our analogue design 
(1-3), the charge of the N-terminal region was maintained (Table 1).  Despite that analogues did 
not show any activity suggesting that proper folding and/or complete sequence is essential for  
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Figure 3.  (a) Antibacterial activity of LeuA and analogues against C. divergens and L. 
monocytogenes.  The MIC values represent peptide concentration that inhibited the growth by 
50%.  Data are represented as means ± standard errors of the means.  The values are results of at 
least three independent measurements.  (b)  Dose dependent decrease in antimicrobial activity of 
LeuA in the presence of analogue 1 against C.divergens.  Antimicrobial activity is expressed as 
optical density at 600 nm ± standard deviation. 
 
 
peptide bactericidal activity.  In addition, it is important to note that in class IIa bacteriocins like 
divercin V41, peptide fragment from the C-terminal domain (from residue 18 to 43) displays 
activity.33  On the other hand, a change in the N-terminal domain in the native sequence while 
Peptide 
MICa (nM) 
C. divergens  L. monocytogenes 
Wild type LeuA48 35 35 
Synthetic LeuA 39 ± 0.2 37 ± 0.4 
1 - - 
2 - - 
3 - - 
-, no activity detected up to 200 µM.  Each assay against the two 
strains was repeated at least three times. 
(a) 
(b) 
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keeping the remaining sequence intact led to complete loss of activity, as observed for analogue 
1.  Likewise, fragment from C-terminal region of pediocin PA-1 (from residue 20 to 34) did not 
display activity but were able to specifically inhibit the bactericidal activity of 44-residue 
pediocin PA-1.13  Finally, it has been shown that long fragments (15-mer) from the N-terminal of 
class IIa peptides such as pediocin PA-1, mesentericin Y105 and, enterocin CRL35, display 
some antimicrobial activity, however, smaller fragments from the N-terminal are inactive.34 
 
2.4 Structure-Activity Relationship 
In order to understand the structural basis of inactivity of analogues, we next studied their 
solution conformations using CD spectroscopy and MD simulations. 
CD Spectroscopy.  CD spectra of LeuA and analogues were obtained in 90% aqueous 
TFE (pH~2.5) to compare the secondary structure of the peptides.  TFE was used as a solvent as 
class IIa bacteriocins form well-defined secondary structures in membrane mimicking solvents 
like TFE, detergent micelles or vesicles, but are essentially unstructured in water.17, 22  Among 
the three analogues, only analogue 1 displayed significant helical structure as indicated by the 
appearance of a distinct negative band at 208 nm (= -11.4 x 103), a negative shoulder near 220 
nm, and a positive band at 195 nm (Figure 4).  In comparison, analogues 2 and 3 were much less 
structured as observed from the CD spectra.  The CD spectrum of 1 resembled that of LeuA 
suggesting similar helical folding in the two peptides.22  Notably, the CD spectra of synthetic 
LeuA shows similar peaks as observed previously for wild type LeuA22 with a negative band at 
206 nm (θ = -10.5 x 103) and a negative shoulder near 220 nm (θ = -6.0 x 103) suggesting similar 
folding pattern. 
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Figure 4.  Circular Dichroism (CD) spectra of synthetic LeuA and analogues 1, 2, and 3 in 90% 
TFE (0.1% TFA final concentration, pH 2.5) at 200 M concentration. 
 
Homology Modeling and MD Simulations.  The secondary structure of analogue 1 was 
further explored using MD simulations.  First, a homology model of analogue 1 was constructed 
using the 3D structure of native LeuA (PDB code-1CW6 9).22  Homology model was placed in 
the middle of a cubic box (Figure 5a).  The box was filled with solvent (TFE) followed by MD 
simulations at two different temperatures, 298 K and 310 K.  Snapshots were extracted after the 
simulations at each nanosecond and were analysed using VMD software.35  Figure 5b shows the 
overlay of several snapshots during simulation at 298 K.  The peptide formed a stable structure 
with a coiled N-terminal region and C-terminal folded into an -helical conformation.  Clearly, 
the N-terminal region of 1 was very different from the native LeuA.  Next, the simulation was 
conducted at an elevated temperature of 310 K.  Peptide 1 showed the appearance of an N-
terminal -sheet (Figure 5c); however, this conformation was present only for short duration 
toward the end of the simulation (~ 9-10 ns).  Overall, MD results suggest that the C-terminal 
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region of analogue 1 fold more like native LeuA, whereas, the N-terminal region displays 
marked differences from the native peptide. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.  (a) Initial setup of a simulation box with box size X, Y and Z = 6 nm for MD 
simulation of analogue 1.  TFE is rendered in blue, analogue 1 in yellow ribbon, and Na+ and Cl- 
ions in magenta and blue, respectively.  (b) Overlay of snapshots of 1 (9-10 ns) extracted from 
simulation at 298 K.  The superimposed images show that the peptide conformation was stable 
with an N-terminal coil and C-terminal helix. (c) Snapshot of 1 extracted (~9 ns) from simulation 
at 313 K. 
 
 
 
(a) 
 
(a) 
(a) 
 
(a) 
(c) 
 
(c) 
(b) 
 
(b) 
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3. Conclusion 
In conclusion, LeuA analogues (1-3) studied here support earlier investigations that the 
C-terminal region is required for specificity and dictates the antimicrobial profile, whereas, the 
N-terminal sequence is necessary for activity.  Replacement of few N-terminal residues with 
conservative substitutions is allowed as shown previously,19 however, the complete N-terminal 
domain is required for activity.  Further, we found that NCL is a better approach for the solid 
phase synthesis of LeuA like peptides. NCL method gives high yield and is an efficient method 
for obtaining large amounts of LeuA.  The NCL method described here can be utilized in future 
for the synthesis of other class IIa bacteriocins and library of analogues for performing 
comprehensive SAR studies.  NCL method avoids unnecessary repeated synthesis of the 
unaltered sequences in a peptide during analogues syntheses. 
 
4. Experimental Section 
4.1 Synthesis of Peptide Analogues 
Synthesis of peptide analogues 1-3 was carried out on 1.0% DVB cross-linked 
chlorotrityl resin (0.2 mmol, loading 1.05 mmol/g) following the standard Fmoc solid-phase 
peptide chemistry with acid labile side chain protections (t-Bu, Boc, Trt) as described 
previously.36  Peptides were synthesized using MPS 357 automated peptide synthesizer robot 
(Advanced Chemtech Inc., USA).  To assist the coupling of difficult residues (Asn, Ser, and for 
all residues after position 10), increased coupling times were employed.  Test cleavage was 
performed at regular intervals (every 5 amino acids) by adding 50% TFA in DCM to a small 
amount of resin followed by shaking for 30 min at room temperature. The complete peptide 
sequences were released from support with concomitant removal of acid-labile side chain 
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protecting groups using the same procedure as used for the test cleavages.  The filtrate from the 
cleavage reactions was combined with TFA washes (3x 2 min, 1 mL), and concentrated in 
vacuum.  Cold diethyl ether (~15 mL) was added to precipitate the crude cleaved peptide.  After 
trituration for 2 min, the peptides were collected upon centrifugation.  The crude peptides were 
dissolved in 20% aqueous isopropanol and purified on HPLC using a semi-preparative VYDAC 
C8 RP-HPLC column (1 x 25 cm, 5 μm) with an isopropanol/water gradient in the presence of 
0.05% TFA.  The gradient used was 25-95% isopropanol/water in 45 minutes at a flow rate of 
1.0 mL/min.  Pure peptides obtained in 15-30% yield were characterized by analytical reversed-
phase HPLC and MALDI-TOF mass spectrometry (Figure S1, SI).  The purity of the peptides 
was verified to be 95% by reversed-phase chromatography.  The pure lyophilized peptide 
analogues were stored at -20 C under nitrogen. 
 
4.2 Synthesis of LeuA 
The synthesis of native LeuA was attempted using native chemical ligation of two 
fragments, 13-mer N-terminal fragment 1 and 24-mer C-terminal fragment 2. 
 
4.2.1. Synthesis of Fragment 1 Thioester 
In order to obtain higher yield of the thioester for fragment 1, two methods were 
attempted for the synthesis (Figure S2). The first method employed sulfonamide safety catch 
resin, whereas the second method used 2-chlorotrityl resin.  The synthesis of fragment 1 thioester 
using Fmoc chemistry on sulfonamide safety catch resin (4-sulfamylbutyryl AM resin, 0.9 
mmol/g, 0.2 mmol) followed procedure described by Ingenito et al.26  The first amino acid 
glycine (1 mmol, 5 eq) was coupled manually to the resin using coupling agents PyBOP (1 
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mmol) and iPr2EtN (0.75 mmol).  The reaction mixture was agitated for 8 h at -20 C followed 
by 8 hr at r.t. to get maximum loading of the first amino acid27.  After deprotection of the first 
amino acid using freshly prepared 20% piperidine in DMF, rest of the amino acids were coupled 
using DIC/HOBt activation protocol on automated peptide synthesizer.  During the entire 
synthesis, coupling reactions were monitored using ninhydrin test.  After completion of 
synthesis, the full length peptide was released from resin with concomitant removal of acid-labile 
side chain protecting groups and formation of C-terminal thioester.  The resin was first treated 
with DIPEA (2 mmol, 10 eq) and iodoacetonitrile (1.6 mmol, 8 eq) in NMP in dark for 24 h at 
room temperature.  Following this, the resin was washed and ethyl-3-mercaptopropionate (50 eq) 
and sodium thiophenol (0.5 eq) in DMF were added to a final concentration of 1 M.  The 
reaction mixture was agitated for 24 h at r.t.  The resin was filtered and washed with DMF (3 x 2 
mL).  The combined filtrate and washings were collected in flask, vacuum concentrated and 
washed with cold anhydrous diethyl ether to remove traces of mercaptans.  Finally, the amino 
terminal Boc group and the side chain protecting groups were removed from the peptide by 
addition of a cleavage cocktail (95:5:5 TFA/TIS/H2O) and the mixture were stirred at r.t. for 2.5 
h.  The solution was evaporated in vacuum and the residual oil was treated with cold anhydrous 
ether (~15 mL).  The resulting precipitate was collected by centrifugation and freeze dried.  
Precipitate was dissolved in 20% acetonitrile/water and purified by semi-preparative RP-HPLC 
to give pure fragment 1 thioester yield 7% (21 mg, 0.013 mmol).  MALDI-TOF calcd for 
fragment 1, [M+H]+ 1530.1; found 1530.3. 
The second method employed 2-chlorotrityl resin (loading 1.6 mmol/g, 0.2 mmol) for the 
preparation of fragment 1 thioester.  The peptide assembly was achieved following procedure 
described for the analogues except that the N-terminal lysine was Boc-protected.  After peptide 
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assembly, peptide was cleaved from the resin using 1% TFA/DCM (3 x 4 mL, each for 3 min).  
The acidic supernatants were combined in reaction vessel containing DIPEA (6.65 mmol, 1160 
L) to yield a final peptide concentration of 4 mM.  To this solution, ethyl 3-mercatopropionate 
(6 mmol, 30 eq), HOBt (4 mmol, 20 eq), DIC (4 mmol, 20 eq), and additional DIPEA (1.33 
mmol, 230 L) were added. The mixture was stirred overnight and concentrated.  The protected 
peptide thioester was precipitated by multiple triturations with cold diethyl ether followed by 
centrifugation. Deprotection of side chains and N-terminal Boc was carried out as described 
above.  The crude product was purified using semi-preperative RP-HPLC to give pure fragment 
1 thioester with a 33% yield (100 mg, 0.065mmol).  Calcd. [M+H]+ 1530.1, found 1530.7. 
 
4.2.2. Synthesis of Fragment 2 
Synthesis of 24-residue fragment 2, LeuA (14-37), was carried out on 2-chlorotrityl 
chloride resin (0.2-mmol) as described for the analogues.  After purification of the crude peptide 
using RP-HPLC, pure fragment 2 was obtained with 55% yield.  MALDI-TOF calcd for 
fragment 2, [M + H]+ 2536.1; found 2536.6. 
 
4.2.3. Native Chemical Ligation 
The chemical ligation of unprotected linear peptide fragments 1 and 2 was done 
following literature protocol.29, 37  Fragment 1 (0.004 mmol, 6 mg) and fragment 2 (0.004 mmol, 
10 mg) were dissolved in freshly degassed sodium phosphate buffer (0.2 M) containing 
guanidine HCL, (6 M, pH 7.5), and the ligation reaction was started by addition of a mixture of 
thiophenol (4%) and benzylmecaptan (4%).  The solution was stirred at 25 °C for 24 hr under 
argon at r.t. and monitored by semi-preparative RP-HPLC and MALDI-TOF MS.  The ligation 
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reaction was completed after 24 hr.  The precipitate was collected, freeze dried, followed by 
purification with RP-HPLC method and characterization.  MALDI-TOF calcd for reduced linear 
LeuA, [M+H]+ 3930.7; found [M+H]+ 3930.3; overall yield 30%. The pure peptide was 
subjected to oxidative folding (disulfide formation) by air oxidation in freshly degassed Tris 
buffer (50 mM, pH 8.4).  Briefly, peptide (10.3 µmol, 41 mg) was dissolved in Tris buffer at a 
concentration of 1 mg/mL, and 20% DMSO was added to the buffer to enhance peptide 
solubility and oxidation.  The solution was gently stirred in an open-air flask for 48 h, and the 
reaction was monitored using Ellman test38 and mass spectrometry (Figure S3).  Oxidized 
peptide was subjected to RP-HPLC to obtain pure cyclized LeuA in 70% yield.  MALDI-TOF 
calcd [M+H]+ 3928.7, found [M+H]+ 3929.1.  The overall yield of LeuA using NCL method was 
21%. 
Leu A was also prepared using Fmoc-SPPS on Cl-trityl resin where 37 amino acids were 
added linearly followed by peptide cleavage from resin and oxidation (disulfide formation). 
Using this method, the overall yield of cyclized LeuA after purification was 4.2%. 
 
4.3 Antimicrobial Activity 
Peptide stock solutions (25 µM) were prepared in methanol/water (1:3) and serial 
dilutions were made as required.  Peptide concentrations of the stock solutions was determined 
by measuring UV absorbance at 280 nm following literature procedure.39  Antimicrobial activity 
assay followed by determination of minimum inhibitory concentrations (MICs) were done using 
the liquid growth inhibition assay in microtiter plates as described previously.36  The indicator 
strains used were Carnobacterium divergens UAL9 (grown in APT broth at 25 C) and Listeria 
monocytogenes ATCC 15313 (TSYBE, 37 C).  The indicator strains were obtained from the 
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culture collection of CanBiocin Inc. (Edmonton, Alberta, Canada).  MICs were defined as the 
peptide concentration that inhibited the growth of the indicator strain by 50%.  For the 
competition experiments using the liquid growth inhibition assay, a range of concentrations of 
analogue 1 (0-100 M) was incubated with indicator strain (C. divergens, diluted 1:100) in the 
presence of LeuA (slightly above its MIC, 50 nM).  The final volume of each well of the 
microtiter plate was made 200 L with the culture medium.  The microtiter plate culture was 
incubated overnight at 25 ºC, after which the growth of the indicator strain was measured 
spectrophotometrically at 600 nm using microtitre plate reader (TECAN, Männedorf, 
Switzerland). 
 
4.4 Characterization of Leu A analogues 
 
4.4.1. CD Spectroscopy 
CD spectra of LeuA analogues 1-3 and synthetic LeuA were obtained using an Olis CD 
spectrometer (Georgia, USA) in a thermally controlled quartz cell with 0.02 cm path length over 
196-250 nm.  Peptide samples with a final concentration of 200 M were prepared in 2,2,2-
trifluoroethanol (90% TFE) containing 0.1% aqueous TFA (pH~2.5).  The baseline scan was 
performed by taking the buffer alone and subtracted from experimental readings.  Data were 
collected every 0.05 nm and were average of 6 scans.  The normalized CD data was expressed in 
units of molar ellipticity per residue (deg cm2 dmol-1) and plotted versus the wavelength. 
 
4.4.2. Molecular Dynamic Simulations 
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MD simulation of peptide analogue 1 was conducted using GROMCAS as described 
previously.22, 40  BLAST 41 and FASTA 42 sequence alignment tools were used to search for other 
similar sequences apart from LeuA.  Analogue 1 displayed high sequence identity with LeuA 
and the solution NMR structure of LeuA in TFE (PDB code 1CW6)9 was used to construct 
homology model of 1 using the magic fit tool in the VMD-software.35  The homology model was 
chosen as the starting structure for MD simulations using GROMACS MD simulation package  
(GROMOS96 force field).43, 44  TFE was used to solvate the simulation box and simulations were 
conducted in the NPT ensemble at 298 or 313 K using periodic boundary conditions.  Weak 
coupling of the peptide to a solvent bath of constant temperature was maintained using the 
Berendsen thermostat 45 and pressure was controlled using the Berendsen algorithm at 1 bar with 
a coupling constant 4 ps, using a compressibility of liquid TFE of 1.22 x 10-4 and 1.34 x 10-4 kJ-1 
mol nm3 at 298 and 313 K, respectively.46  The electrostatic and van der Waals interactions were 
truncated at a cutoff distance of 1.2 nm.  The integration time step was 2 fs, and the coordinates 
and velocities were saved every 2 ps. The LINCS algorithm was used to restrain all bond lengths.  
A cubic box (6×6×6 nm3) was constructed and used to run the simulation.  Parameters for TFE 
solvent were prepared according to Fioroni et al.46  Homology model of analogue 1 was placed 
in the centre of the box by replacing the TFE molecules equivalent to the peptide size.  The N-
terminal was positively charged (NH3
+) and C-terminal was considered to be negatively charged 
(COO-).  In the sequence, residues Asp, Arg, Glu and Lys were charged and His residues were 
kept neutral.  Sufficient counter ions (Na+, Cl-) were added to make the system electro neutral 
and to provide a final concentration of ~100 mM.  Energy within the system was minimized 
before MD simulation using 200 steps of the steepest descent energy minimization method in 
order to relax any steric conflicts generated during the set-up.  The equilibration of the analogue 
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1-TFE system was achieved by performing a 3 ns MD run with positional restrain on the peptide 
molecule.  Following this, a full MD run of 10 ns was performed without any restraints at 298 K 
followed by at 310 K.  Snapshots of the peptides were extracted from 1-10 ns. Simulations were 
analyzed using various GROMACS post processing routines.43  Swiss-Pdb Viewer 47 and VMD35 
softwares were used to visualize, analyse and superimpose structures. 
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